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Abstract
Background Standardized outcome reporting is crucial for trial evidence synthesis and translation of findings into clini-
cal decision-making. The OMERACT 2.0 Filter and COMET outcome domain taxonomy propose frameworks for consis-
tent reporting of outcomes. There is an absence of a uniform dermatology-specific reporting strategy that uses precise
and consistent outcome definitions.
Objectives Our aim was to map efficacy/effectiveness outcomes assessed in dermatological trials to the OMERACT
2.0 Filter as a starting point for developing an outcome taxonomy in dermatology.
Methods We critically appraised 10 Cochrane Skin Reviews randomly selected from all 69 Cochrane Skin Reviews
published until 01/2015 and the 220 trials included covering a broad spectrum of dermatological conditions and inter-
ventions. Efficacy/effectiveness outcomes were mapped to core areas and domains according to the OMERACT 2.0 Fil-
ter. The extracted trial outcomes were used for critical appraisal of outcome reporting in dermatology trials and for the
preliminary development of a dermatology-specific outcome taxonomy.
Results The allocation of 1086 extracted efficacy/effectiveness outcomes to the OMERACT 2.0 Filter resulted in a hier-
archically structured dermatology-specific outcome classification. In 506 outcomes (47%), the outcome concept to be
measured was insufficiently described, hindering meaningful evidence synthesis. Although the core areas assessed in
different dermatology trials of the same condition overlap considerably, quantitative evidence synthesis usually failed
due to imprecise outcome definitions, non-comparable outcome measurement instruments, metrics and reporting.
Conclusions We present an efficacy/effectiveness outcome classification as a starting point for a dermatology-speci-
fic taxonomy to provide trialists and reviewers with the opportunity to better synthesize and compare evidence.
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Introduction
In the rapidly developing field of clinical research, it is necessary
for clinicians and health policy decision makers to have access to
synthesized evidence, since clinical and health policy decisions
should always be based on the best current available evidence.1
Over the last decade, it has become increasingly clear that lack of
comparability and the failure to consistently assess all relevant
outcomes in clinical trials constitutes a major obstacle in synthe-
sizing evidence. Thus, limiting the use of trial information for
clinical decision-making.2,3 At a primary study level, it is recog-
nized that trialists frequently use very different terminologies for
the same underlying outcome.4
One approach to solving these problems is the development
and implementation of a Core Outcome Set (COS). A COS is an
internationally agreed, minimum set of outcomes that are con-
sistently measured and reported in a standardized way for all tri-
als within a health condition.5 Ideally, a COS defines both the
outcome domains (i.e. WHAT to measure) and the outcome
measurement instruments most suitable to measure these out-
come domains (i.e. HOW to measure).
The Cochrane Skin-Core OUtcome Set INitiative (CS-COU-
SIN) is a multi-professional international initiative that supports
COS groups working to improve and standardize outcome
assessment and reporting in dermatology clinical trials and
reviews.6,7 Currently, 17 COSs are in development within CS-
COUSIN for a broad range of dermatological conditions such as
atopic dermatitis,8,9 acne, nail psoriasis,10 vitiligo,11 different
types of skin cancer,12 vascular malformations,13 congenital mel-
anocytic naevi,14 hidradenitis suppurativa,15 and incontinence
associated dermatitis16 (www.cs-cousin.org/). A major problem
is that across different dermatological conditions, various
expressions and definitions for identical or similar outcome
domains are used (e.g. clinical signs of atopic eczema,17 progres-
sion-free survival in melanoma6). Precise and consistently used
outcome definitions as well as a sufficiently detailed hierarchy of
sub-domains within the outcome domains are still missing for
dermatology. This creates a significant barrier not only towards
the development of COSs in dermatology, but also for indexing,
referencing and identifying relevant clinical trials and reviews.
In 2014, the international initiative Outcome Measures in
Rheumatology (OMERACT) introduced a conceptual framework
for outcome classification and suggested that all COS should
include at least one outcome from each of the four core areas
‘death’, ‘life impact’, ‘pathophysiological manifestations’ and
‘resource use/economical impact’.18 Building on the OMERACT
2.0 Filter and other frameworks, the international Core Outcome
Measures in Effectiveness Trials (COMET) group recently intro-
duced a generic taxonomy for outcome domain classification in
medicine.19 One of its 29 outcome domains is ‘skin and subcuta-
neous tissue outcomes’ within the core area ‘physiological/clini-
cal’, but further sub-domains are not specified within this relatively
broad spectrum of potential outcome domains in dermatology.
Therefore, the authors pointed out that the COMET taxonomy
needs to be extended, with a higher level of detail for different
specific areas of medicine (e.g. skin and subcutaneous tissue).
A common dermatology-specific outcome taxonomy provides
a resource to standardize outcome definitions, classifies out-
comes and underlying concepts of outcomes and suggests a sys-
tematic hierarchy of outcome domains, sub-domains and
outcome concepts. The combination of a taxonomy and the cor-
responding structured terminology for outcomes/outcomes
domains forms the basis for a kind of reference book. The devel-
opment and expansion of the taxonomy can lead to an improve-
ment in the consistent use of results with corresponding
definitions in the future. Furthermore, such a taxonomy of out-
comes is important to allow dermatologists and all other
research users to better identify relevant outcomes in trials and
reviews and thus make evidence identification and synthesis pos-
sible and much more efficient.
To move forward in the development of an urgently needed
dermatological taxonomy, we sought to map the broad spectrum
of outcomes assessed in dermatological trials, investigating a wide
range of conditions, to theOMERACT 2.0 Filter. Furthermore, we
aimed to quantify the utilization of specific outcome domains/sub-
domains within the corresponding core areas to identify their dis-
tribution and highlight dermatology outcome domain priorities.
Methods
We critically appraised 10 Cochrane Skin systematic reviews ran-
domly selected from all 69 Cochrane Skin Reviews, published
until January 2015, and the underlying clinical trials included
within these reviews. The simple random sample was drawn
using the statistical software R. The primary focus of the review
was to investigate the (i) quality (sufficient and clear outcome
reporting) and (ii) degree of consistency and completeness in
outcome reporting in clinical trials. In particular, we collected
the level of detail in outcome reporting and whether all compo-
nents of outcome reporting were provided.
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Taking the outcome frameworks by Zarin et al.,20 Chan
et al.21 and the OMERACT Filter 2.018 into account, an outcome
within this work was described by the following eight compo-
nents (Fig. 1):
1 core area e.g.: ‘life impact’;
2 outcome domain/sub-domain e.g.: ‘perception of health’ >
‘single symptom’ > ‘pain’;
3 outcome concept to measure e.g.: ‘reduction’, ‘progression’,
‘response’;
4 measurement instrument e.g.: score: ‘visual analogue scale 1–10’;
• including the setting ‘who’ measured/assessed the out-
come (patient self-/external (relative/representative)
reported, clinical or laboratory assessment
5 time of measurement e.g.: ‘2 weeks after treatment’;
6 analysis metric e.g.: ‘change from baseline’;
7 method of aggregation e.g.: ‘mean difference’, ‘frequency of
changes’, ‘odds ratio’;
8 statistical test procedure e.g.:
• statistical test: ‘t test’, ‘Mann–Whitney test’
• modelling approach: ‘logistic regression’, ‘cox regres-
sion’ (non-adjusted, adjusted for, e.g. age and sex)
The review protocol was registered in the international
Prospective Register of Systematic Reviews (PROSPERO;
CRD42015025005). Detailed description of data sources and
data extraction procedures have been reported elsewhere.4
Data source and extraction
We used different data sources for this project. First, a random
sample of 10 systematic reviews from 69 Cochrane Skin Reviews,
published until January 2015, were drawn. Predefined inclusion
criteria were set to include only trials published in English, Ger-
man, Italian or Spanish and reported efficacy/effectiveness out-
comes other than biomarkers.
Information on trial characteristics, interventions, study pop-
ulations and the efficacy/effectiveness outcomes relevant for the
Cochrane reviews was retrieved from the Archie database pro-
vided by Cochrane Skin (https://archie.cochrane.org/). The
Archie database contains data originally extracted by the
Cochrane Review teams during their review process. This data
source was supplemented by data extraction from the original
trial publications for relevant information not covered in Archie,
such as information on the trial outcomes not considered as rel-
evant from the Cochrane Reviewers. These outcomes will be ter-
med as ‘additional outcomes’ subsequently. Two reviewers
independently extracted all ‘additional outcomes’ and other
trial/ outcome information into a standardized electronic tem-
plate form in MS Access using the Archie database and the origi-
nal trial publications.
Allocation process of outcome domains and sub-domains
The framework of the OMERACT 2.0 Filter was used to map all
extracted efficacy/effectiveness outcomes to outcome domains such
as ‘acceptance of care’, ‘daily life impact’ or ‘perception of health’
in an iterative process performed by two reviewers with dermato-
logical and methodological expertise (JS, TL). We first listed all
outcomes and mapped them into preliminary outcome domains.
Then, we reviewed the resulting lists to determine whether we
could combine these outcome domains and re-categorized them if
considered appropriate. After completeness and consistency
checks, a classification list of outcome domains was obtained. In
order to take different levels of complexity into account, we used
up to two levels of sub-domains (1st, 2nd). This allowed the devel-
opment of a more detailed hierarchical structure on the outcome
domains as shown in Fig. 2. Figure 2 also provides definitions for
the different outcome components. The final list of outcome
domains was mapped to the OMERACT core areas (‘death’, ‘life
impact’, ‘pathophysiological manifestations’, ‘resource use/eco-
nomic impact’)18 (Fig. S1). Using the linkage of trial outcomes to
outcome domains/sub-domains, the frequencies of the domains and
core areas overall and within each reviewwere calculated.
Results
Study and outcome selection
A total of 220 out of 242 trials (91%) met the inclusion criteria
and could be retrieved for analysis (Fig. S2). Overall, these trials
covered 1086 efficacy/effectiveness outcomes. 395 of these out-
comes (36%) were considered as relevant outcomes for the
Figure 1 Hierarchical schema of outcome specification based on
Zarin et al.20 and Chan et al.21
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corresponding Cochrane reviews. The remaining 691 additional
outcomes (64%) were not included in the Cochrane reviews and
were extracted from the trial publications. In total, an average of
4.9 (range 1–34) outcomes per trial were assessed with an aver-
age of 2.8 (range 1–14) different measurement instruments.
Allocation of domains to the OMERACT 2.0 Filter
In an iterative process, all 1086 outcomes identified were
mapped to outcome domains and core areas (Table 1). This pro-
cedure led to the grouping of outcomes to domains and up to
two levels of sub-domains (1st level >2nd level). All resulting out-
come domains/sub-domains could be mapped to one of the four
core areas as defined by the OMERACT 2.0 filter. The frequen-
cies in Table 1 show the relevance of the different core areas in
the different sets of dermatology trials. ‘Pathophysiological man-
ifestations’ such as physical signs of skin disease were considered
in all 10 included systematic reviews. Table 2 shows the resulting
list of assessed outcome domains/sub-domains and their corre-
sponding frequency distributions.
Level of detail in study outcome reporting
The detail of the efficacy/effectiveness outcome description var-
ied considerably between trials. Unfortunately, synthesizable
descriptions of outcomes for data extraction (Fig. 1) were not
provided in the majority of the included trial publications. Fre-
quently, very broad concepts such as ‘response’, ‘clearance’ or
‘progression’ were used, but with either divergent or unclear/not
reported underlying definitions, even within a group of trials for
a specific condition. In summary, in 506 out of 1086 cases, we
were unable to extract the outcome domain (WHAT to measure)
in such depth that an evidence synthesis would be feasible. The
outcome concept to measure therefore needs to be defined more
clearly within the outcome domain. Table 3 shows the most fre-
quently investigated outcome domains in the most prominent
core areas ‘life impact’ and ‘pathophysiological manifestations’.
It is clear that the mapped outcomes overlapped between trials
from a moderate to a high extent at domain level. However, for
quantitative evidence synthesis, it is also crucial that all other
components of the outcome definition are reported, too (Fig. 1).
Table 4 illustrates such divergence. Even if trial investigators
measured the same outcome (according to an outcome defini-
tion that is reduced to the first five components), an incompara-
bility of this outcome across the trials remains. The reason is
that this simplification of outcome definition to the described
five components is not enough to enable a quantitative evidence
synthesis: using this simplified outcome definition about 48% of
all potentially synthesizable outcomes were not comparable. If
the missing components were included, the extent of
Figure 2 Hierarchical schema of outcome components: WHAT to measure based on Boers et al.18
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incomparability for quantitative evidence synthesis would
increase further. The following example illustrates the aforemen-
tioned problem of data synthesis. The condition ‘common cuta-
neous warts’ was analysed with 150 different outcomes. Within
the investigated trials, 143 outcomes were mapped to the out-
come domain ‘global disease severity’ (most frequent domain
here). Of these 143 outcomes, nine were assessed with the same
measurement instrument, but only five outcomes reported the
same time of measurement. Thus, of initially 143 ‘global disease
severity’ outcomes, only five outcomes have the potential for a
quantitative evidence synthesis.
Discussion
Main findings
This review extends previous research on dermatology outcomes
in several aspects. This study shows that all identified efficacy/ef-
fectiveness outcomes of dermatology trials included in a ran-
domly selected set of dermatological Cochrane Reviews could be
successfully mapped to the four core areas as defined by the
OMERACT 2.0 Filter. The OMERACT 2.0 Filter therefore
appears to be a valid starting point for a dermatology-specific
taxonomy. In 2018, OMERACT updated this framework
(OMERACT Filter 2.1) in order to improve the precision and
accuracy. The four core areas have been renamed but have a
similar meaning compared to the previous version.22
In terms of outcome content, our review highlights the vast
predominance of physician-reported ‘pathophysiological mani-
festations’ in all trial sets included. The patient-relevant core area
‘life impact’, where most of the patient-reported outcomes like
disease symptoms and quality of life are included, were not con-
sidered in the majority of trials.
Themain contribution of our study is providing a starting point
of a dermatology-specific outcome taxonomy mapping outcome
domains/sub-domains to the four core areas ‘death’, ‘life impact’,
‘pathophysiological manifestations’, ‘resource use/economic
impact’18 as the highest hierarchical structure. Such an outcome
taxonomy is an important resource of COS developers in derma-
tology, as well as for trialists, guideline developers and everyone
else who develops or uses dermatology trials and reviews.
Another important finding of our study is that the common
level of outcome description is insufficient in most of the trial
publications to be used for quantitative evidence synthesis. In
almost half of the outcomes examined, we could not clearly
break them down into the underlying outcome components.
This lack of detail severely restricts the potential of quantitative
evidence synthesis.
The use of a list of components to describe an outcome, which
was proposed by Zarin et al.,20 Chan et al.21 and the OMERACT
Filter 2.0,18 is very helpful to define and classify outcomes. How-
ever, in our view, we need a more detailed description of the
WHAT to measure. In addition to the outcome domains, it is alsoT
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Table 2 Proposed starting point for a dermatology outcome taxonomy based on the underlying trials of included Cochrane reviews
Core area
(OMERACT 2.0)
Domain Sub-domain (1st level) Sub-domain (2nd level)
Trials† Outcomes‡ Trials† Outcomes‡ Trials† Outcomes‡
Death (7/4) Overall survival 7% 4% Overall survival
(all cause death)
6% 2%
Treatment
related mortality
1% <1%
Life impact
(41/23)
Acceptance
of care
4% 1% Compliance/
adherence
2% 1%
Coping 2% 1% Itching
behaviour
(scratching)
<1% <1%
Skin (care)
behaviour
1% <1%
Activity
participation
1% <1% Sports activity
participation
<1% <1%
Daily life impact 3% <1%
Family impact 2% 1% Burden for mother <1% <1%
Mother-child
interaction
1% <1%
Parental QOL 1% <1%
Patient
satisfaction
3% 1% Treatment
satisfaction
2% <1% Satisfaction with
cosmetic
outcome
1% <1%
Satisfaction
with treatment
effectiveness
2% <1%
Perception
of health
34% 19% Perception of
cosmetic outcome
<1% <1%
Perception of
general symptoms
3% 1% Appetite/thirst 1% <1%
Sleeping
problems
1% <1%
Perception of
global disease
2% <1% Perception of
eczema severity
1% <1%
Disease
related
sleeping
problems
1% <1%
Perception of
global health
1% <1%
Single symptoms 39% 20% Burning 1% <1%
Dandruff <1% <1%
Dryness 3% 1%
Dyspareunia 1% <1%
Erythema/ redness 23% 8%
Flakiness <1% <1%
Itching 7% 2%
Lichenification 2% 1%
Pain 4% 1%
Papules <1% <1%
Pruritus 15% 4%
Scaling 4% 1%
Seborrhea <1% <1%
Soreness <1% <1%
Stinging <1% <1%
Unspecified
dermatological
symptoms
5% 2%
Visibility
appearance
1% <1%
Quality of life 6% 1% Quality of
life, generic
2% <1%
Quality of life,
dermatologic
4% 1%
Quality of life, oncologic <1% <1%
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Table 2 Continued
Core area
(OMERACT 2.0)
Domain Sub-domain (1st level) Sub-domain (2nd level)
Trials† Outcomes‡ Trials† Outcomes‡ Trials† Outcomes‡
Pathophysiological
manifestations
(98/69)
Clinical
assessment
98% 67% Global disease
severity
90% 40% Appearance of nail 10% 5%
Global severity
of eczema
<1% <1%
Presence of wart 32% 13%
Visibility of
disease signs
<1% <1%
Single signs 26% 17% Bleeding <1% <1%
Crusting 3% 1%
Dandruff <1% <1%
Desquamation 1% <1%
Dryness 4% 1%
Erythema/
redness
19% 7%
Excoriation 3% 1%
Exudation 1% <1%
Fissures 1% <1%
Greasiness 1% <1%
Infiltration 2% <1%
Inflammation 1% <1%
Lichenification 3% 1%
Maceration <1% <1%
Oedema 1% <1%
Oozing <1% <1%
Papulation 1% <1%
Peeling <1% <1%
Roughness <1% <1%
Scaling 12% 3%
Sebum secretion <1% <1%
Skin texture <1% <1%
Surface damage <1% <1%
Ulceration 1% <1%
Vesiculation <1% <1%
Weeping <1% <1%
Combinations of
two or more signs
19% 10% Erythema, oedema,
excoriation,
lichenification
Erythema, oedema,
excoriation,
lichenification,
crusting, dryness
(. . .)
Laboratory
assessment
4% 1% Biomarkers <1% <1%
Colonization 2% <1%
Histo-pathology 2% 1%
Physiological
skin
assessment
1% <1%
Resource use/
economical
impact (11/4)
Direct costs <1% <1% Financial and
temporal burden
<1% <1%
Healthcare 10% 4% Treatment visits <1% <1%
Treatment utilization 10% 3% Indication for
concomitant
treatment
1% <1%
Utilization of
specific treatment
9% 3%
Sick leave <1% 1%
†Indicates the percentage of all 220 trials that investigated the core area, domain or sub-domain.
‡Indicates the percentage of all 1,086 outcomes that investigated the core area, domain or sub-domain.
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crucial to specify the outcome concept measured when describing
the outcome (Fig. 1). We understand this part of the component
(WHAT to measure) as a deeper and more precise description of
an outcome domain for a specific health condition with respect to
a clinical target that will be investigated (e.g.: ‘occurrence’, ‘re-
lapse’, ‘progression/reduction’). Considering the single symptom
itching (within the core area of ‘life impact’), different concepts
of WHAT to measure are feasible (e.g. the occurrence of itching
after 2 weeks intervention, time of progression-free itching, the
itching status, itch severity, itch frequency, itch intensity or the
fully remission of itching).
In many dermatological studies, only the outcome domain or
its concept was reported. It makes a big difference, whether – for
example – erythema is considered as a sub-domain of the out-
come domain clinical signs to describe the ‘intensity of skin
lesions’, or if the degree of erythema is used as an indicator for
‘disease remission’ or ‘progression’ as an outcome on its own.23
In summary, even if the same outcome domain is investigated in
different trials, outcome definitions are still too broad to be able
to summarize these outcomes across the trials.
Quantitative evidence synthesis will only be fully possible if all
of the described components (Fig. 1) were reported and have
key similarities across trials. This comparability is the rationale
for developing COSs. COS developers aim to standardize rele-
vant outcomes for trials to enable an effective evidence synthesis.
Despite these efforts, developing a COS is an important step for-
ward; however, a COS is still a too broad concept, without align-
ing all components of the outcome definition in a COS.
Therefore, we recommend the consideration and standardized
reporting of all proposed components (including statistical tests
to be applied) of an outcome for every efficacy/effectiveness trial
to harmonize across-trial outcome synthesis.
Future taxonomy development
Hierarchy is required for different medical fields. Therefore, we
used a bottom-up approach to provide a basis of mapped outcome
domains for further development of a dermatology-specific exten-
sion of this taxonomy. This approach was based on the common
procedure for identification of potential outcome domains in the
context of COS development.24 In the future, using the taxonomy
other dermatology-specific conditions might require the inclu-
sion of further levels of sub-domains in order to minimize the loss
of information or to describe newly introduced domains.
Limitations
The source of data was restricted to a random sample of 10
Cochrane Skin Reviews, and therefore, only a selection of certain
conditions could be considered. Due to the time restriction, new
developments in standardized reporting in dermatology trials
after 2014 could not be considered. However, we believe that the
random sample lead to a saturation of themes and covers an
appropriate range of dermatological topics and diseases.T
ab
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In this investigation, only efficacy and effectiveness outcomes
were included. Therefore, outcome domains, which typically also
refer to safety outcomes, were not represented in the proposed
taxonomy and should be included at a later stage of develop-
ment.
When reviewing the proposed taxonomy, it must be acknowl-
edged that sub-domain differentiation is subjective. For example,
the HOME initiative considered clinical signs and disease symp-
toms to be core outcome domains25 whereas the recently published
update of the OMERACT 2.1 filter considers both sub-domains as
a part of clinical manifestations without explicit reflection of who
determined this clinical manifestation and whether it is visible
(clinical signs of skin diseases) or not (symptoms).26
Additionally, only two raters performed the iterative alloca-
tion process, although all authors reviewed the results and con-
tributed to the conceptual framework. Despite these limitations,
this endeavour provides the first crucial steps towards providing
a dermatology-specific taxonomy.
Implications for further research
To the best of our knowledge, this study represents the first
attempt to provide a framework and resource for an extension
of the general taxonomy of Dodd et al.19 to a specific medical
area: dermatology. CS-COUSIN plans to further expand the cur-
rent state of development to support and accelerate the exten-
sion of a dermatology-specific taxonomy as a resource for study
trialists, reviewers and COS developers (www.cs-cousin.org/).
The next step of this development process will be an extension
and possible revision of the outcome domain mapping by consid-
ering further conditions with respect to efficacy/effectiveness,
safety, and biomarker outcomes to complement the dermatol-
ogy-specific taxonomy. Outcome lists of COS groups or system-
atic reviews of outcome research in dermatology will be a
resource for this.
In order to reduce the diversity of terminologies used by differ-
ent COS initiatives and groups in dermatology, it is of crucial
importance to provide a taxonomy with definitions at different
outcome domain levels. Therefore, we propose a consensus process
with relevant clinical experts, methodologists and patient represen-
tatives to develop a consensus based dermatology-specific exten-
sion of the general taxonomy proposed by theCOMET group.
After this comprehensive process of taxonomy development,
it is necessary to support the translation of the research results,
assess the extent of feasibility and support capability in derma-
tology research. Furthermore, it would be meaningful to exam-
ine the transferability of the development process of the
aforementioned suggestions to other medical areas.
Conclusion
In this study, we mapped outcomes to the OMERACT 2.0 Filter
and provide a resource of potentially relevant outcome domains
for dermatological trials. This hierarchically structured outcome
domain list may be used as a starting point for a dermatology-
specific extension of the general taxonomy proposed by the
COMET group to provide a framework for trialists, reviewers
and COS developers to facilitate reporting and evidence synthe-
sis of trial outcomes. Even if similar outcome constructs are
measured in trials, there is substantial variation regarding use of
measurement instruments, time of measurements and methods of
aggregation. These variations do not allow firm meta-analysis or
qualitative comparison of evidence from different trials, indicat-
ing that only defining core outcome domains and measurement
instruments are not sufficient for meaningful evidence synthesis.
COS should go further, and at least standardize the time of
measurements, the specific analysis metric and the method of
aggregation. For dermatology, there is a clear need for out-
come taxonomy and a corresponding standardized reporting
terminology.
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